Expression of Th1- Th2- and Th17-associated cytokines in laryngeal carcinoma

Oncology Letters

Volumn 12, Issue 3, 2016, Pages 1941-1948

  Xu, Xiaoqun ^a   Wang, Rui ^b   Su, Qinghong ^a   Huang, Haiyan ^a   Zhou, Peng ^a   Luan, Junwen ^a   Liu, Jingsheng ^a   Wang, Junfu ^a   Chen, Xuemei ^c  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b HEZE MUNICIPAL HOSPITAL   (China)

^c THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Cytokine; Laryngeal carcinoma; T helper 1; T helper 17; T helper 2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER PROGNOSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOCOMPATIBILITY; HISTOLOGY; HUMAN; INFLAMMATION; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TH1 TH2 BALANCE; TH17 CELL; VERY ELDERLY; WESTERN BLOTTING;

EID: 84979656408     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4854     Document Type: Article

References (56)

1. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauqer S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F and Galon J: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 71: 1263-1271, 2011.
2. Rajput S and Wilber A: Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed) 2: 176-183, 2010.
3. Li W, Chen C, Saud SM, Geng L, Zhang G, Liu R and Hua B: Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment. BMC Complement Altern Med 14: 153, 2014.
4. Bierie B and Moses HL: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21: 49-59, 2010.
5. Deng S, Hu B, Shen KP and Xu L: Inflammation, macrophage in cancer progression and chinese herbal treatment. J Basic Clin Pharm 3: 269-272, 2012.
6. Su Z, Sun Y, Zhu H, Liu Y, Lin X, Shen H, Chen J, Xu W and Xu H: Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis. Immunol Res 58: 118-124, 2014.
7. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454: 436-444, 2008.
8. Zhu J and Paul WE: Heterogeneity and plasticity of T helper cells. Cell Res 20: 4-12, 2010.
9. Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y and O’Shea JJ: Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 21: 425-434, 2010.
10. Wei H, Sun R, Xiao W, Feng J, Zheng C, Xu X and Tian Z: Type two cytokines predominance of human lung cancer and its reverse by traditional Chinese medicine TTMP. Cell Mol Immunol 1: 63-70, 2004.
11. Dong C: Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol 6: 329-333, 2006.
12. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238, 2006.
13. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, et al: T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28: 29-39, 2008.
14. Ouyang W, Kolls JK and Zheng Y: The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467, 2008.
15. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, Izawa S and Fujii H: Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101: 1947-1954, 2010.
16. Gaur P, Singh AK, Shukla NK and Das SN: Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum Immunol 75: 330-337, 2014.
17. Wrzesinski SH, Wan YY and Flavell RA: Transforming growth factor-beta and the immune response: Implications for anticancer therapy. Clin Cancer Res 13: 5262-5270, 2007.
18. Jakowlew SB: Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 25: 435-457, 2006.
19. Chu EA and Kim YJ: Laryngeal cancer: Diagnosis and preoperative work-up. Otolaryngol Clin North Am 41: 673-695 2008.
20. Starmer HM, Tippet DC and Webster KT: Effects of laryngeal cancer on voice and swallowing. Otolaryngol Clin North Am 41: 793-818, 2008.
21. Karatzanis AD, Psychogios G, Waldfahrer F, Kapsreiter M, Zenk J, Velegrakis GA and Iro H: Management of locally advanced laryngeal cancer. J Otolaryngol Head Neck Surg 43: 4, 2014.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
23. Lee KJ (ed): Essential Otolaryngology Head and Neck Surgery. 7th edition. McGraw-Hill Medical Publishing Division, New York, 1999.
24. Chen XM, Xu XQ, Sun K, Hallett WH, Zhao JD and Zhang DL: NKG2D ligands expression and NKG2D-mediated cytotoxicity in human laryngeal squamous carcinoma cells. Scand J Immunol 67: 441-447, 2008.
25. Tian Z, Shen X, Feng H, Gao B: IL-1 beta attenuates IFN-alpha beta-induced antiviral activity and STAT1 activation in the liver involvement of proteasome-dependent pathway. J Immunol 165: 3959-3965, 2000.
26. Maarof G, Bouchet-Delbos L, Gary-Gouy H, Durand-Gasselin I, Krzysiek R and Dalloul A: Interleukin-24 inhibits the plasma cell differentiation program in human germinal center B cells. Blood 115: 1718-1726, 2010.
27. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
28. Jaseviciene L, Gurevicius R, Obelenis V, Cicenas S and Juozulynas A: Trends in laryngeal cancer incidence in Lithuania: A future perspective. Int J Occup Med Environ Health 17: 473-477, 2004.
29. Lu ST, Wei KR, Yu BH, Chen Z, Liang Z, Fang F and Zheng WB: Analysis of laryngeal cancer incidence rate in Zhongshan City in 1970-1999. Xian Dai Zhong Liu Yi Xue 12: 158-160, 2004.
30. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, Ang KK, Gay G, Stewart A and Robinson RA: Laryngeal cancer in the United States: Changes in demo - graphics, patterns of care, and survival. Laryngoscope 116 (9 Pt 2 Suppl 111): S1-S13, 2006.
31. Gourin CG, Conger BT, Sheils WC, Bilodeau PA, Coleman TA and Porubsky ES: The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope 119: 1312-1317, 2009.
32. Hashibe M, Boffetta P, Zaridze D, Shangina O, Szeszenia-Dabrowska N, Mates D, Fabiánová E, Rudnai P and Brennan P: Contribution of tobacco and alcohol to the high rates of squamous cell carcinoma of the supraglottis and glottis in Central Europe. Am J Epidemiol 165: 814-820, 2007.
33. Shangina O, Brennan P, Szeszenia-Dabrowska N, Mates D, Fabiánová E, Fletcher T, t’Mannetje A, Boffetta P and Zaridze D: Occupational exposure and laryngeal and hypopharyngeal cancer risk in Central and eastern Europe. Am J Epidemiol 164: 367-375, 2006.
34. Ma L, Liang Y, Fang M, Guan Y, Si Y, Jiang F, and Wang F: The cytokines (IFN-gamma, IL-2, IL-4, IL-10, IL-17) and Treg cytokine (TGF-beta1) levels in adults with immune thrombocy- topenia. Pharmazie 69: 694-697, 2014.
35. Li P, Spolski R, Liao W and Leonard WJ: Complex interactions of transcription factors in mediating cytokine biology in T cells. Immunol Rev 261: 141-156, 2014.
36. Ma W, Wang K, Du J, Luan J and Lou G: Multi-dose parecoxib provides an immune protective effect by balancing T helper 1 (Th1), Th2, Th17 and regulatory T cytokines following laparoscopy in patients with cervical cancer. Mol Med Rep 11: 2999-3008, 2015.
37. Murugaiyan G and Saha B: Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175, 2009.
38. Mosmann TR and Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146, 1996.
39. Yamamura M, Modlin RL, Ohmen JD and Moy RL: Local expression of antiinflammatory cytokines in cancer. J Clin Invest 91: 1005-1010, 1993.
40. Oshikawa K, Yanagisawa K, Ohno S, Tominaga S and Sugiyama Y: Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med 165: 1005-1009, 2002.
41. Chen YM, Yang WK, Whang-Peng J, Tsai CM and Perng RP: An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. Lung Cancer 31: 25-30, 2001.
42. Kharkevitch DD, Seito D, Balch GC, Maeda T, Balch CM and Itoh K: Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with meta- static melanoma. Int J Cancer 58: 317-323, 1994.
43. Chtanova T and Mackay CR: T cell effector subsets: Extending the Th1/Th2 paradigm. Adv Immunol 78: 233-266, 2001.
44. Farrag TY, Koch WM, Cummings CW, Goldenberg D, Abou-Jaoude PM, Califano JA, Flint PW, Webster K and Tufano RP: Supracricoid laryngectomy outcomes: The Johns Hopkins experience. Laryngoscope 117: 129-132, 2007.
45. Page C, Mortuaire G, Mouawad F, Ganry O, Darras J, Pasquesoone X and Chevalier D: Supracricoid laryngectomy with cricohyoidoepiglottopexy (CHEP) in the management of laryngeal carcinoma: Oncologic results. A 35-year experience. Eur Arch Otorhinolaryngol 270: 1927-1932, 2013.
46. Agarwal S, Misra R and Aggarwal A: Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 35: 515-519, 2008.
47. Gu Y, Hu X, Liu C, Qv X and Xu C: Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol 142: 109-114, 2008.
48. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK and Sasaki H: IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177-6189, 2005.
49. Nabeshima K, Inoue T, Shimao Y and Sameshima T: Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 52: 255-264, 2002.
50. Li A, Dubey S, Varney ML, Dave BJ and Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170: 3369-3376, 2003.
51. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, et al: Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923, 2008.
52. Kryczek I, Wei S, Szeliga W, Vatan L and Zou W: Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359, 2009.
53. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, et al: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373, 2008.
54. Cirée A, Michel L, Camilleri-Bröet S, Jean Louis F, Oster M, Flageul B, Senet P, Fossiez F, Fridman WH, Bachelez H and Tartour E: Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 112: 113-120, 2004.
55. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP and Dutton RW: Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 184: 4215-4227, 2010.
56. Honorati MC, Neri S, Cattini L and Facchini A: IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 133: 344-349, 2003.